Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Mesoblast Ltd (MESO)
Price$14.87Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.3M | $17.2M | $5.9M | $7.5M | $10.2M | $7.4M | $32.2M | $16.7M | $17.3M | $2.4M | $42.5M |
| Gross profit | $103.6M | $12.1M | $5.9M | $7.5M | — | — | — | — | — | — | — |
| Gross margin | 86.14% | 70.17% | 100.00% | 100.00% | — | — | — | — | — | — | — |
| Research & development | $97.5M | $34.8M | $39.7M | $52.8M | $32.8M | $53.0M | $56.2M | $59.8M | $65.9M | $58.9M | $50.0M |
| Operating expenses | $154.8M | $74.5M | $62.1M | $76.8M | — | — | — | — | — | — | — |
| Operating income | −$51.3M | −$62.4M | −$56.2M | −$69.3M | — | — | — | — | — | — | — |
| Operating margin | −42.62% | −363.08% | −952.63% | −923.73% | — | — | — | — | — | — | — |
| EBITDA | −$37.0M | −$80.1M | −$65.1M | −$62.7M | — | — | — | — | — | — | — |
| EBITDA margin | −30.78% | −465.51% | −1,103.66% | −835.32% | — | — | — | — | — | — | — |
| Net income | −$57.5M | −$102.1M | −$88.0M | −$81.9M | −$91.3M | −$98.8M | −$77.9M | −$89.8M | −$35.3M | −$76.8M | −$4.1M |
| Net profit margin | −47.82% | −593.92% | −1,490.27% | −1,091.71% | −894.59% | −1,329.18% | −242.38% | −537.01% | −203.51% | −3,184.70% | −9.70% |
| Basic EPSper basic share | — | -$0.08 | -$0.09 | -$0.11 | -$0.13 | -$0.16 | -$0.15 | -$0.18 | -$0.08 | -$0.19 | -$0.01 |
| Diluted EPSper diluted share | — | -$0.08 | -$0.09 | -$0.11 | -$0.13 | -$0.16 | -$0.15 | -$0.18 | -$0.08 | -$0.19 | -$0.01 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
MORGAN STANLEY | 718.61K |
BlackRock, Inc. | 664.28K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 457.74K |
GOLDMAN SACHS GROUP INC | 395.61K |
BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 259.7K |
UBS Group AG | 200.05K |
Arax Advisory Partners | 168.02K |
BANK OF AMERICA CORP /DE/ | 100K |
Penbrook Management LLC | 87.08K |
M&G PLC | 59.1K |
Quadrature Capital Ltd | 53.13K |
LPL Financial LLC | 47.87K |
LAZARI CAPITAL MANAGEMENT, INC. | 47.42K |
Rialto Wealth Management, LLC | 46.5K |
GROUP ONE TRADING LLC | 44.03K |
ROYAL BANK OF CANADA | 44K |
TWO SIGMA INVESTMENTS, LP | 43.4K |
GEODE CAPITAL MANAGEMENT, LLC | 33.75K |
JANE STREET GROUP, LLC | 33.15K |
&PARTNERS | 27.57K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 10, 2026Form 4 | George GregoryDirector,TenPercentOwner | BuyOrdinary Shares · indirect | 2.32M | $1.48 | $3.44M | 8.32M |
| Apr 10, 2026Form 4 | George GregoryDirector,TenPercentOwner | BuyOrdinary Shares · indirect | 2.32M | $1.48 | $3.44M | 8.32M |
| Apr 9, 2026Form 4 | George GregoryDirector,TenPercentOwner | BuyOrdinary Shares · indirect | 10.0K | $1.41 | $14.1K | 13.59M |
| Apr 9, 2026Form 4 | George GregoryDirector,TenPercentOwner | BuyOrdinary Shares · indirect | 10.0K | $1.43 | $14.3K | 13.58M |
| Apr 9, 2026Form 4 | George GregoryDirector,TenPercentOwner | BuyOrdinary Shares · indirect | 10.0K | $1.43 | $14.3K | 13.57M |
Community posts
Mesoblast gains FDA clearance for a new Ryoncil potency assay
Mesoblast ($MESO) received FDA approval to use a new potency assay for the release and stability testing of newly manufactured commercial Ryoncil batches. The TIBA assay is intended to identify changes in product potency, including those as ...
